MX2023015398A - Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina. - Google Patents

Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Info

Publication number
MX2023015398A
MX2023015398A MX2023015398A MX2023015398A MX2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A MX 2023015398 A MX2023015398 A MX 2023015398A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
antitrypsin deficiency
antitrypsin
deficiency
Prior art date
Application number
MX2023015398A
Other languages
English (en)
Spanish (es)
Inventor
Nigel Ramsden
David John Fox
James Andrew Huntington
Original Assignee
Centessa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals Uk Ltd filed Critical Centessa Pharmaceuticals Uk Ltd
Publication of MX2023015398A publication Critical patent/MX2023015398A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023015398A 2021-06-15 2022-06-15 Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina. MX2023015398A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
MX2023015398A true MX2023015398A (es) 2024-04-29

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015398A MX2023015398A (es) 2021-06-15 2022-06-15 Composiciones y su uso para el tratamiento de la deficiencia de a1-antitripsina.

Country Status (12)

Country Link
US (1) US12673050B2 (enExample)
EP (1) EP4355328A1 (enExample)
JP (1) JP7854001B2 (enExample)
KR (1) KR20240027693A (enExample)
CN (1) CN117794538A (enExample)
AU (1) AU2022295130A1 (enExample)
BR (1) BR112023026510A2 (enExample)
CA (1) CA3223130A1 (enExample)
GB (1) GB202108523D0 (enExample)
IL (1) IL309355A (enExample)
MX (1) MX2023015398A (enExample)
WO (1) WO2022263816A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3391038B2 (ja) 1991-12-26 2003-03-31 富士レビオ株式会社 カルボン酸アミド誘導体
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2012097371A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
US12673050B2 (en) 2026-07-07
JP2024523406A (ja) 2024-06-28
US20240197707A1 (en) 2024-06-20
AU2022295130A1 (en) 2024-01-18
GB202108523D0 (en) 2021-07-28
BR112023026510A2 (pt) 2024-03-05
CN117794538A (zh) 2024-03-29
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CL2008003096A1 (es) Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras.
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BR112013006953A2 (pt) composto, composições farmacêutica e anti-helmíntica, uso de um composto, kit, e, método de tratamento de uma doença
BR112015028482A2 (pt) implante cirúrgico que compreende uma camada que tem aberturas
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
BR112012002134B8 (pt) compostos inibidores de apaf-1
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA200801997A1 (ru) Новые соединения
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
NO20083780L (no) Topisk sammensetning omfattende en antibakteriell substans
BR112013006030A2 (pt) composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2011003144A1 (es) Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05).
CY1116840T1 (el) Χρηση 24-norudca
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
CL2008002384A1 (es) Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CL2024000829A1 (es) Formas sólidas de un inhibidor ge glyt1
PY22104936A (es) "inhibidores y/o degradadores de bckdk"